You are trying to load the Human Atlas. Either you do not have the newest version of Adobe Flash®, or you have JavaScript disabled, both of which are required to use this system.

Adjust Font Size
 
 

  Find A Doctor

Profile Image

Chaitra Ujjani, MD

Instructor of Medicine, Hematology and Oncology

Specialties

Primary Specialty: 
Hematology/Oncology
Secondary Specialty: 
Lombardi Comprehensive Cancer Center
 

Special Interests

  • Hematologic Malignancies
  • Clinical research in Lymphoma and Leukemia
  • Development of new cancer drugs
 

Education

Undergraduate:
University of Alabama at Birmingham, Birmingham, AL, 2001
Medical School:
University of Alabama School of Medicine, Birmingham, AL, 2005
Internship:
Hospital of the University of Pennsylvania, Philadelphia, PA, 2006
Residency:
Hospital of the University of Pennsylvania, Philadelphia, PA, 2008
Fellowship:
Hematology/Oncology, Georgetown University Hospital, Washington, DC, 2011
Certification(s):
Hematology and Medical Oncology, 2011
Internal Medicine, 2008
 

Profile Information

Languages: English
 

Contact/Office Information

1-202-444-1212
1-202-444-4971

MedStar Georgetown University Hospital
3800 Reservoir Rd., NW
Lombardi Comprehensive Cancer Center
Podium B, Second Floor, Room 413
Washington, DC 20008

 

Department Web Pages:

 

Additional Information

Publications:

  1. Ujjani, C and Cheson, B. Efficacy of Bendamustine in Rituximab-Refractory Indolent B-cell non-Hodgkin Lymphoma: Review of a Pivotal Trial. Future Oncology. 7:1:9-14. 2011.
  2. Ujjani, C and Cheson, B. Bendamustine in Chronic Lymphocytic Leukemia and non-Hodgkin’s Lymphoma. Expert Review of Anti-Cancer Therapy. 10:9:1353-65. 2010.
  3. Ujjani, C and Cheson, B. Monoclonal Antibodies in Advanced B-cell Lymphomas. Oncology. 24:2:156-166. 2010.
  4. Mato A, Luger S, Heitjan D, Mikkelson M, Olson E, Ujjani C, et al. Elevation in serum lactate at the time of Febrile Neutropenia (FN) in hemodynamically-stable patients with Hematologic Malignancies (HM) is associated with the development of septic shock within 48 hours. Cancer Biology and Therapy. 9:8. 2010.
  5. Mato A, Luger S, Heitjan D, Mick R, Halpern S, Shah P, Jacobs S, Olson E, Schuster S, Ujjani C, et al. Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignancies. Cancer Biology and Therapy. 8:12: 1097-1102. 2009.